



SideROS raised €1 Million funding to accelerate the development of its lead candidate in cancer

Based on promising proof of concept results, SideROS will join Paris Biotech Santé incubator to initiate non-clinical pivotal investigations prior to first-in-man studies

Paris, August 27, 2020 - [SideROS](#), a French biotechnology company specialized in oncology, announced the closing of a 1 million euros funding to tackle relapse and metastasis in cancer. SideROS bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persisten cancer cells, refractory to conventional treatments and associated to metastasis and relapse. The role of iron is ubiquitous regardless the origin of cancer cells, suggesting that its first candidate could target various types of cancer.

The €1 M funding from private and public investment is brought half by a pool of Business Angels with international expertise in the pharmaceutical industry in the form of equity, and half by the support of Bpifrance and Région Ile-de-France in the form of grants and loans. Proceeds will be used to accelerate SideROS development to achieve major milestones in terms of non-clinical safety and efficacy data as well as industrial manufacturing scale-up of ironomycin needed to move to first-in-man studies.

“This investment from qualified Business Angels and public support will allow us to accelerate our development and reach strategic milestones to move forward to pivotal regulatory toxicology studies in early 2021 and to the design of our first clinical trial planned for 2022 aiming at improving the condition of patients affected by life-threatening diseases lacking an effective treatment. We are very proud to have been selected by Paris Biotech Santé, a new step in SideROS structural development” stated Lucie Mondoulet, CEO at SideROS.

SideROS harnesses research work from CNRS, notably conducted by the research team of Raphaël Rodriguez in that field.

“SideROS is born based on my past 10 years of research when elucidating and publishing the role of iron in the maintenance of persisten cancer cells and developed a first-in-class lead chemical molecule, ironomycin, aiming at eradicating those cells refractory to conventional treatments and associated to metastasis and relapse” said Raphaël Rodriguez, Co-Founder and Chairman of the Scientific Committee of SideROS, and CNRS Research Director at Curie Institute.

“As business angels we are excited to invest in SideROS: strong science, solid proof of concept data, game-changing patents, a clear and transparent strategy, an excellent medical environment and outstanding people to lead and steer development. SideROS has all ingredients for success!” stated Bertrand Dupont, co-founder of DBV Technologies, leading Business Angel pool.

“The global market for unmet needs in cancer is continuously increasing despite targeted therapeutics available. With this funding, we are securing our agile development plan aiming at generating the core non-clinical evidence supporting our lead product with its unique mechanism of action to tackle cancer types prone to metastasis and relapse, and lacking effective treatment” said Nathalie Donne, business advisor to SideROS.

Starting from September 2020, SideROS will integrate Paris Biotech Santé incubator, to get expertise from their network in the complex field of drug development in oncology and support in the future steps of fundraising.

About SideROS

SideROS, founded in 2019 by Raphaël Rodriguez and Robin Rivaton, bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells, refractory to conventional treatments and associated to metastasis and relapse. The role of iron is ubiquitous in cancer, suggesting that our small molecules can target various types of cancer. SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking effective treatments. SideROS has received Deeptech label from Bpifrance in 2019. (www.sideros.bio; <https://www.linkedin.com/company/sideros-bio>).

About Paris Biotech Santé

Paris Biotech Santé incubator is dedicated to human health, was founded in 2007 by University Paris Descartes, INSERM, ESSEC, and Ecole Centrale in Paris. PBS is a partner of Pasteur Institute, Curie Institute, AP-HP, AFSSAPS, FHF, Genopole, and university Paris Diderot-Paris 7 and Canceropole.

Press contact for SideROS


Anne REIN

StrategiesImage (S&I)

+33 (0)6 03 35 92 05

anne.rein@strategiesimage.com



 FIT Health is supported by the EIT, a body of the European Union

